ILDR2 is a novel B7-like protein that negatively regulates T cell responses

Iris Hecht*, Amir Toporik, Joseph R. Podojil, Ilan Vaknin, Gady Cojocaru, Anat Oren, Elizabeta Aizman, Spencer C. Liang, Ling Leung, Yosef Dicken, Amit Novik, Nadav Marbach-Bar, Aziza Elmesmari, Clare Tange, Ashley Gilmour, Donna McIntyre, Mariola Kurowska-Stolarska, Kay McNamee, Judith Leitner, Shirley GreenwaldLiat Dassa, Zurit Levine, Peter Steinberger, Richard O. Williams, Stephen D. Miller, Iain B. McInnes, Eyal Neria, Galit Rotman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The B7-like protein family members play critical immunomodulatory roles and constitute attractive targets for the development of novel therapies for human diseases. We identified Ig-like domain-containing receptor (ILDR)2 as a novel B7-like protein with robust T cell inhibitory activity, expressed in immune cells and in immune-privileged and inflamed tissues. A fusion protein, consisting of ILDR2 extracellular domain with an Fc fragment, that binds to a putative counterpart on activated T cells showed a beneficial effect in the collagen-induced arthritis model and abrogated the production of proinflammatory cytokines and chemokines in autologous synovial-like cocultures of macrophages and cytokine-stimulated T cells. Collectively, these findings point to ILDR2 as a novel negative regulator for T cells, with potential roles in the development of immune-related diseases, including autoimmunity and cancer.

Original languageEnglish (US)
Pages (from-to)2025-2037
Number of pages13
JournalJournal of Immunology
Issue number6
StatePublished - Mar 15 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'ILDR2 is a novel B7-like protein that negatively regulates T cell responses'. Together they form a unique fingerprint.

Cite this